Google Ads for TRT and HRT Clinics: Certification, Controlled-Substance Rules and the December 2026 DEA Deadline

What does a TRT or HRT clinic need before running Google Ads?

A clinic that prescribes testosterone or other hormones through an online consultation needs LegitScript healthcare certification as a telemedicine provider and then Google’s own healthcare certification before Google will serve its ads in the US. Without certification, a clinic can still use prescription drug terms in ad text and on landing pages in the US. It cannot keyword-target them, which rules out bidding on “testosterone” searches. Testosterone is also a Schedule III controlled substance, so the DEA’s telemedicine rules, currently extended to 31 December 2026, shape what the landing page can promise.

Men’s-health and hormone clinics sit where three regimes meet: Google’s healthcare policies, controlled-substance law, and state medical licensing. The common mistake is to treat it like a normal local-services account, where the ads get written first and the business model is classified afterwards.

Which clinic models need which certification?

Business model	Does Google treat it as prescription drug services?	What to plan for
Telehealth TRT/HRT (online consult, prescription, shipped medication)	Yes. Google names telemedicine providers and online pharmacies as businesses subject to the policy	LegitScript healthcare certification (telemedicine), then Google healthcare certification; partner pharmacies generally need LegitScript certification too
Hybrid (online booking, in-person first visit, remote follow-up and refills)	Often. Google says it “errs on the side of caution” for pages that appear to facilitate online prescribing	Assume certification is needed if the site offers remote prescribing or refills
In-person clinic only (book an appointment, treatment on site)	Less likely, if nothing on the site facilitates online prescription or dispensing	Keyword targeting of drug terms still requires certification; ad and landing-page wording must stay accurate
Clinic that also sells peptides or compounded products online	Yes for the prescription side. Unapproved Substances may apply to specific products	Separate the catalogues; see our guides on compounded GLP-1s and Unapproved Substances

For telemedicine in the US, Google’s Healthcare and medicines policy says it “allows telemedicine providers if they’re accredited by LegitScript’s Healthcare Merchant Certification Program” and that “advertisers must also be certified with Google.” LegitScript’s published application asks telemedicine applicants to list every jurisdiction they serve and explain how they comply in each one. It also asks directly whether the business prescribes or dispenses controlled substances. Our LegitScript guide covers cost and timing.

Can a TRT clinic bid on ‘testosterone’ keywords?

Only with certification. Google’s Restricted drug terms policy says that for campaigns targeting the US, Canada or New Zealand, “while you don’t need to be certified in order to use prescription drug terms in ads and landing pages, you must be certified in order to keyword-target these terms.” The Prescription drug services policy adds that advertisers “must be approved by Google Ads to bid on keywords containing prescription drug terms,” and only in listed locations.

Testosterone is a prescription drug in the US, and the DEA lists it in Schedule III. Google’s list of monitored drug terms is non-exhaustive. We could not open the current version during this check, so assume “testosterone” is monitored. For an uncertified clinic this leaves a narrow set of options:

• Service and condition terms that do not name a drug may be eligible, for example “men’s health clinic” or “hormone clinic near me”. Every ad and landing page still has to stay accurate and non-promotional about prescription drugs where required.
• Broad match on any hormone keyword will match drug-name searches. Add negatives for drug names and brand names, and review search terms weekly.
• Do not use coded spellings or abbreviations to get around the restriction. Google’s Unapproved Substances policy separately bans names “confusingly similar” to controlled substances.

Why is hCG a problem in TRT advertising?

Many TRT protocols include human chorionic gonadotropin. Google’s Unapproved Substances policy lists, among the products it does not allow “regardless of any claims of legality”, “products containing human chorionic gonadotropin (hCG) in relation to weight loss or weight control, or when promoted in conjunction with anabolic steroids.” Merchant Center’s healthcare policy uses the same wording.

Under the US Controlled Substances Act (21 U.S.C. § 802(41)), testosterone is classed as an anabolic steroid. Google does not publish how it applies this line to clinical TRT protocols. We treat it as a real risk and advise three things. Keep hCG out of ad text, keywords and sitelinks. Do not publish “TRT + hCG” package pages as ad destinations. Never pair hCG with weight-loss language. Unapproved Substances violations can escalate to account suspension, so this is not a line to test.

What targeting restrictions apply to hormone clinics?

Google’s Personalized advertising policy lists health among its sensitive interest categories with targeting restrictions. In practice, audience tactics common elsewhere are limited here, such as remarketing to people who visited a “low T symptoms” page or building lists from patient data. Two consequences:

• Keyword intent and location do more of the work, so the keyword and negative lists deserve more attention than in other verticals.
• Patient data should not flow into ad platforms by default. Intake answers, diagnoses and lab values are health information. See our HIPAA-conscious conversion tracking guide for a setup that measures bookings without sending health information.

For lead-generation clinics, the most useful measurement signal is usually a qualified consultation imported from the clinic’s system as an offline conversion, not a form fill. Google now handles those imports through Data Manager. From 15 June 2026, Google said offline conversion and enhanced-conversions-for-leads uploads would move to the Data Manager API and be blocked in the Google Ads API, except for developer tokens that qualified for legacy access.

What does the December 2026 DEA deadline mean for TRT advertising?

The Ryan Haight Act generally requires an in-person medical evaluation before a controlled substance is prescribed. Since 2020, temporary DEA and HHS rules have allowed DEA-registered practitioners to prescribe Schedule II–V medications by audio-video telemedicine without one. The fourth temporary extension, published in the Federal Register on 31 December 2025, is effective from 1 January 2026 through 31 December 2026.

A permanent “special registration for telemedicine” was proposed in January 2025. Legal commentators reported that DEA sent a final rule to the White House Office of Information and Regulatory Affairs on 25 August 2026. As of mid-September 2026 its text was not public, and no fifth extension had been published. Three outcomes are possible: another extension, a final rule with new requirements, or the flexibilities lapsing.

If…	What changes on the advertising side
The flexibilities are extended again	Little immediately; keep monitoring the new end date
A final special registration rule takes effect	Your clinic’s eligibility, patient states and process may change; landing pages must describe the process you actually follow
The flexibilities lapse without replacement	“No in-person visit required” copy may stop being true for new patients. Leaving it live risks misrepresentation and regulatory problems

What should a TRT or HRT landing page say, and avoid?

• Say who prescribes. Licensed clinicians, the states you serve, and the fact that treatment requires evaluation and may not be appropriate for everyone.
• Describe the process accurately. Labs, consultation, follow-up monitoring and pricing, including what is and is not included.
• Avoid outcome promises. Energy, libido, body composition and “anti-ageing” results stated as expected outcomes run into Google’s unreliable-claims rules. They also create FTC substantiation exposure.
• Avoid guaranteed prescriptions. “Get approved in minutes” and “guaranteed TRT” wording suggests prescribing is not a medical decision. That is a problem for LegitScript review as well as for Google.
• Separate peptide and longevity offers. If the clinic also offers peptides, keep them off TRT ad destinations until you have checked them against Unapproved Substances and FDA’s 2026 compounding status. Our remediation checklist covers product-page wording.

To see where a clinic stands before applying for certification, the Readiness Score takes about five minutes. If you want help planning the certification and campaign sequence, book a strategy call.

Sources

• Google Advertising Policies Help — Healthcare and medicines (US telemedicine and Unapproved substances), Prescription drug services, Restricted drug terms, Restricted targeting in personalized advertising, Misrepresentation
• Google Ads Help — Updates to your enhanced conversions settings (Data Manager API migration, 15 June 2026)
• DEA Diversion Control — Controlled Substances – Alphabetical Order (testosterone, Schedule III)
• Federal Register — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (31 December 2025; effective through 31 December 2026)
• Mondaq — DEA appears close to finalizing telemedicine special registration (24 September 2026; secondary source for the OIRA submission)
• LegitScript — Healthcare Certification application questions and certification standards

Checked 2026-09-30. The DEA position may change before 31 December 2026; check the Federal Register. Not legal or medical advice.

Frequently asked